Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Morphine + glucagon is a combination of two drugs, morphine and glucagon. Morphine is an opioid analgesic that acts primarily on the central nervous system to relieve moderate to severe pain by binding to and activating the mu-opioid receptor, resulting in analgesia, sedation, and euphoria. Glucagon is a peptide hormone used mainly for the treatment of severe hypoglycemia and as a diagnostic aid in radiologic exams; it works by activating hepatic glucagon receptors, stimulating glycogenolysis and increasing blood glucose levels. There are no widely recognized or approved pharmaceutical products combining these two agents into a single formulation or therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on morphine + glucagon.